Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ophiobolin A C21-isopropyl ketone is a synthetic analog of ophiobolin A, a sesterterpenoid fungal metabolite isolated from *Bipolaris* species. Developed by researchers at Texas State University and collaborating institutions, this compound was designed to investigate the structure-activity relationship of the C21-aldehyde group, which is a potential metabolic liability in the parent molecule. Ophiobolin A is known to exhibit potent cytotoxicity against glioblastoma (GBM) and glioma stem cells (GSCs) by inducing paraptosis, characterized by cytoplasmic vacuolization. However, the C21-isopropyl ketone derivative demonstrated inferior potency compared to the natural aldehyde, suggesting that increasing steric bulk at the C21 position negatively impacts the compound's ability to induce cell death in glioma models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ophiobolin A C21-isopropyl ketone.